STOCK TITAN

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced the grant of 2,200 restricted stock units to a newly hired employee. This grant, approved by Atara's Board of Directors Compensation Committee, falls under the 2018 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4). The grant date is set for July 1, 2024, with the units vesting over four years. The first 25% will vest on the first quarterly vesting date following the first anniversary of the vesting commencement date. The remaining units will vest quarterly over the next three years, contingent on continuous employment with Atara. This disclosure complies with Nasdaq Listing Rule 5635(c)(4).

Positive
  • None.
Negative
  • None.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 2,200 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of July 1, 2024, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.

Investor and Media Relations

Jason Awe, Ph.D.

Senior Director, Corporate Communications & Investor Relations

(805) 217-2287

jawe@atarabio.com

Source: Atara Biotherapeutics, Inc.

FAQ

What did Atara Biotherapeutics announce on July 1, 2024?

Atara Biotherapeutics announced the grant of 2,200 restricted stock units to a newly hired employee under the 2018 Inducement Plan.

What is the vesting schedule for the restricted stock units granted by Atara Biotherapeutics?

The restricted stock units will vest over four years. 25% will vest on the first quarterly vesting date after the first anniversary, and the remaining units will vest quarterly over three years.

How many restricted stock units did Atara Biotherapeutics grant to the new employee?

Atara Biotherapeutics granted 2,200 restricted stock units to the new employee.

Under which rule did Atara Biotherapeutics report the recent stock grant?

Atara Biotherapeutics reported the stock grant under Nasdaq Listing Rule 5635(c)(4).

Which plan covers the recent stock unit grant by Atara Biotherapeutics?

The recent stock unit grant by Atara Biotherapeutics is covered under the 2018 Inducement Plan.

Atara Biotherapeutics, Inc

NASDAQ:ATRA

ATRA Rankings

ATRA Latest News

ATRA Stock Data

58.46M
4.46M
22.15%
50.83%
11.21%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS